Valneva’s Chikungunya Vaccine Advances With Pediatric Trial, Phase 3 in 2026 - Valneva (NASDAQ:VALN)

Valneva’s Chikungunya Vaccine Advances With Pediatric Trial, Phase 3 in 2026 - Valneva (NASDAQ:VALN)

Valneva SE (NASDAQ:VALN) on Thursday announced six-month antibody persistence and safety data for its Phase 2 trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, Ixchiq, in 304 children, according to a press release. Partially funded by the Coalition for Epidemic Preparedness Innovations (CEPI), with support from the European Union, the trial is intended to support a pivotal Phase 3…

Valneva reports data from Phase II chikungunya vaccine trial in children

Valneva has reported encouraging six-month safety and antibody persistence data from the multi-centre Phase II trial, VLA1553-221, of Ixchiq.The post Valneva reports data from Phase II chikungunya vaccine trial in children appeared first on Clinical Trials Arena.

Six-month IXCHIQ chikungunya vaccine data demonstrates sustained antibody levels

Six-month results from the phase 2 VLA1553-221 trial aligned with initial data and demonstrated immune response at day 180 among patients aged 1 to 11 years.

Antibodies Remain 6 Months After Chikungunya Vaccine Administered in Youngest Children

Valneva’s immunization, Ixchiq, was well tolerated in children ages 1 to 11 years regardless of the dose or previous chikungunya infection.

Valneva's Chikungunya Vaccine Advances With Pediatric Trial, Phase 3 In 2026

Valneva SE (NASDAQ:VALN) on Thursday announced six-month antibody persistence and safety data for its Phase 2 trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, Ixchiq, in 304 children, according to a press release. Partially funded…